Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer | Zendy

DJ Kerr | Zendy; GJ Rustin | Zendy; S.B. Kaye | Zendy; Peter Selby | Zendy; N M Bleehen | Zendy; Peter Harper | Zendy; MH Brampton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer

Author(s) -

DJ Kerr,

GJ Rustin,

S.B. Kaye,

Peter Selby,

N M Bleehen,

Peter Harper,

MH Brampton

Publication year - 1995

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1995.498

Subject(s) - medicine , colorectal cancer , ovarian cancer , bolus (digestion) , oncology , phases of clinical research , cancer , clinical trial , urology

Rhizoxin is a tubulin-binding anti-neoplastic agent which is active in a range of murine tumour models. The recommended schedule, of intravenous (i.v.) bolus administration at a dose of 2 mg m-2 every 3 weeks, has been assessed in three phase II trials of ovarian, renal and colorectal cancer. In general terms the drug was fairly well tolerated, but the response rate was disappointing: 0/18, colorectal cancer; 0/18, renal cancer; 1 partial response (PR)/17, ovarian cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research